Velocity Pharmaceutical Development LLC

Velocity Pharmaceutical Development LLC

Velocity Pharmaceutical Development LLC

Overview
Date Founded

2011

Headquarters

400 Oyster Point Boulevard,Suite 202,South San Francisco, CA 94080

Type of Company

Private

Employees (Worldwide)

11 - 50

Industries

Retail: Drug Stores
Management Consulting
Biotechnology
Wholesale: Consumer Non-Durables/Sundries

Company Description

Velocity Pharmaceutical Development LLC develops pharmaceutical drugs. It identifies drug candidates, target markets and designing and managing outsourced clinical trials. The firm seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. The company was founded by David Collier, Ed Schnipper, Jim Larrick and Andy Perlman in 2011 and is headquartered in South San Francisco, CA.

Website
Executives & Employees

Chief Executive Officer & Managing Director

Chief Medical Officer & Managing Director

Chief Medical Officer & Managing Director

Chief Medical Officer & Managing Director

Venture Partner

Board of Directors

President at Nabu Health Care Consulting

Chief Medical Officer at Protagonist Therapeutics, Inc.

Managing General Partner, Information Technology at Presidio Partners

Managing Director at InCube Venture Partners LLC

Former Vice President-Oncology & Rheumatology Strategic Business Unit at Biogen, Inc.

Paths to Velocity Pharmaceutical Development LLC
Potential Connections via
Relationship Science
You
Velocity Pharmaceutical Development LLC
Investors
Details Hidden

Advisor at 8 Partners

Details Hidden

Co-Founder at PanGenetics BV

Details Hidden

CMEA Capital focuses on investments in the life sciences, high technology and energy & materials sectors. They invest in both early- and late-stage ventures.Within the life sciences, the firm invests in biotechnology companies that engage in drug discovery and development. They invest in all stages in medical device companies with evolutionary products that have shorter R&D pathways. They also invest at mid- and late stages in companies with revolutionary products that tend to have longer R&D pathways.Within the high technology sector, CMEA focuses on high performance electronics companies in the consumer electronics and semiconductors markets.Within the energy & materials sector, the firm focuses on future fuels, premium power, alternative generation technologies, energy intelligence and energy efficient products.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Velocity Pharmaceutical Development LLC. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Velocity Pharmaceutical Development LLC's profile does not indicate a business or promotional relationship of any kind between RelSci and Velocity Pharmaceutical Development LLC.